H igh blood levels of local anesthetics (LAs), in particular the potent and long-lasting LA bupivacaine, are a dreaded complication of regional anesthesia that can cause therapy-refractory cardiac and central nervous system symptoms, and ultimately death. 1 The consequent establishment of safety steps, such as aspiration and ultrasound-guided nerve blocks, has caused the number of reported cases of devastating complications to decline significantly. 2 However, severe events of LA toxicity still occur with an incidence of 3.5 to 9.8 per 10,000. 3, 4 Until quite recently, an efficient therapeutic option for such intoxications was unavailable. Weinberg et al. 5 demonstrated that infusion of a lipid emulsion improved the outcome of resuscitations after intoxication with bupivacaine in dogs. Subsequent studies indicate that lipids are indeed effective for treatment of LA-induced cardiac arrhythmias and cardiac failure. 6, 7 In addition, more than 12 case reports of successful lipid-based treatment of patients have been published, and several national and international organizations recommend the use of lipid emulsions for treatment of LA intoxication. 8, 9 The mechanism(s) through which lipids alleviate LA-induced cardiotoxic events remains largely unknown. A common hypothesis is that the fat dispersion in plasma acts like a "lipid sink," that is, that lipids absorb and thus reduce the unbound fraction of bupivacaine in plasma. 10, 11 Furthermore, a positive metabolic effect of lipids due to mitochondrial oxidation of fatty acids has been discussed. 12 The high cardiotoxicity of bupivacaine is considered to involve a long-lasting inhibition of Nav1.5, the cardiac α-subunit of voltage-gated Na + channels. 13 It has not yet been explored in detail whether lipid emulsions used for lipid resuscitation directly interact with Nav1.5 to alter biophysical properties, or whether they compromise the ability of bupivacaine to inhibit Nav1. 5 .
In this study, we addressed 2 main questions: (1) whether lipid emulsions directly interact with Nav1.5 and alter distinct biophysical properties and (2) whether lipid emulsions reduce bupivacaine-induced inhibition of Nav1.5. We explored the effects of 2 different lipid emulsions on recombinant human Nav1.5: Intralipid®, composed of long-chain triglycerides (LCTs), and Lipofundin®, a mixture of longand medium-chained triglycerides (LCTs/MCTs). While both emulsions have been successfully used for treatment of systemic LA toxicity in humans, 14, 15 the LCTs emulsion seems to be superior to LCTs/MCTs to absorb bupivacaine and for treatment of bupivacaine-induced arrhythmias. 16, 17 BACKGROUND: Systemic administration of lipid emulsions is an established treatment for local anesthetic intoxication. However, it is unclear by which mechanisms lipids achieve this function. The high cardiac toxicity of the lipophilic local anesthetic bupivacaine probably results from a long-lasting inhibition of the cardiac Na + channel Nav1.5. In this study, we sought to determine whether lipid emulsions functionally interact with Nav1.5 or counteract inhibition by bupivacaine. METHODS: Human embryonic kidney cells expressing human Nav1.5 were investigated by whole-cell patch clamp. The effects of Intralipid® and Lipofundin® were explored on functional properties and on bupivacaine-induced inhibition. RESULTS: Intralipid and Lipofundin did not affect the voltage dependency of activation, but induced a small hyperpolarizing shift of the steady-state fast inactivation and impaired the recovery from fast inactivation. Lipofundin, but not Intralipid, induced a concentration-dependent but voltage-independent tonic block (42% ± 4% by 3% Lipofundin). The half-maximal inhibitory concentration (IC 50 ) values for tonic block by bupivacaine (50 ± 4 µM) were significantly increased when lipids were coapplied (5% Intralipid: 196 ± 22 µM and 5% Lipofundin: 103 ± 8 µM). Usedependent block by bupivacaine at 10 Hz was also reduced by both lipid emulsions. Moreover, the recovery of inactivated channels from bupivacaine-induced block was faster in the presence of lipids. CONCLUSIONS: Our data indicate that lipid emulsions reduce rather than increase availability of Nav1.5. However, both Intralipid and Lipofundin partly relieve Nav1.5 from block by bupivacaine. These effects are likely to involve not only a direct interaction of lipids with Nav1.5 but also the ability of lipid emulsions to absorb bupivacaine and thus reduce its effective concentration. (Anesth Analg 2013;117:1101-8)
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Effects of Lipids and Bupivacaine on Nav1.5
METHODS

Cell Culture
Stably transfected human embryonic kidney 293 cells expressing human Nav1.5 were cultured in Dulbecco's modified Eagle medium (GIBCO-Invitrogen, Karlsruhe, Germany), supplemented with 10% heat-inactivated fetal bovine serum (Biochrom, Berlin, Germany), 1% penicillin/ streptomycin (GIBCO-Invitrogen), 0.4% Zeocin (Invitrogen, Carlsbad, CA) at 37°C in 5% CO 2 . Cells were grown attached in cell culture flasks and were split 3 times a week. For experiments, cells were replated in 35-mm culture dishes and were used within 2 days.
Electrophysiology
Sodium currents were recorded by using the whole-cell configuration of the whole-cell patch-clamp technique. Patch pipettes fabricated from borosilicate glass tubes (GB150EFT-10; Science Products, Berlin, Germany) were pulled to a resistance of 1.0 to 1.8 MΩ after heat polishing. All experiments were conducted at room temperature with an EPC9 patch-clamp amplifier (HEKA Instruments Inc., Bellmore, NY). Currents were filtered at 5 kHz, sampled at 20 kHz, and stored on a PC for off-line analysis using the Pulse/ Pulse Fit software (HEKA Instruments Inc.). The series resistance was compensated by 60% to 80% to minimize voltage errors, and the capacitance artifacts were cancelled using the amplifier circuitry. Linear leak subtraction, based on resistance estimates from 4 hyperpolarizing pulses, was applied before the test pulse and was performed for all experiments.
Experiments were performed with an external solution composed of 40 mM NaCl, 100 mM N-methyl-d-glucamine, 3 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , and 10 mM HEPES (adjusted to pH 7.4 with tetramethylammonium hydroxide). The pipette solution contained 140 mM CsF, 10 mM NaCl, 1 mM EGTA, and 10 mM HEPES (adjusted to pH 7.3 with CsOH). The osmolarity of all solutions was adjusted to 290 to 300 mOsm. Test solutions were applied through a homemade, gravity-driven perfusion system.
Chemicals
Bupivacaine (Sigma-Aldrich, Munich, Germany) was prepared as a stock of 100 mM in dimethyl sulfoxide (DMSO). The highest concentration of DMSO was 1/100 in the solution containing 1 mM bupivacaine. In the most relevant bupivacaine solution with 10 µM, DMSO was as low as 1/10,000. Importantly, DMSO alone diluted to 1/100 did not induce any inhibition of sodium currents (data not shown). Solutions with Intralipid (20%; Sigma-Aldrich) or Lipofundin (20%; Braun, Melsungen, Germany) were prepared directly before the experiments. In all experiments, lipid emulsions were diluted in different concentrations in the external solution with or without bupivacaine and then dispersed at 37°C and 500 rpm for 60 minutes. To avoid different sodium concentrations between the control and lipid dilution, we adjusted the respective control with an appropriate amount of distilled water.
Data Analysis
Data were analyzed with the Pulsefit software package (HEKA Instruments Inc.). Curve fitting and statistical analyses were performed with Origin 6.0 (Microcal Software, Northampton, MA). Statistical comparisons of dependent and independent sets of data were calculated with the paired or unpaired Student t test. Dependent data were extracted from identical cells recorded at 2 different experimental conditions. Independent data were extracted from different populations of cells recorded at identical experimental conditions. "n" denominates the number of recorded cells for each experiment. Statistical significance was determined at P < 0.05 for single comparisons. In those cases in which 3 sets of independent data were compared, the Bonferroni post hoc test was applied to adjust the significance level to 0.017 to account for the possibility of a type I error. Data are presented as mean ± SEM or fitted value ± SE of the fit. For statistical comparisons of data calculated by mathematical fits, we calculated mathematical fits on data of each cell.
To obtain activation curves, the peak conductance, gm, was estimated from the equation gm = INa/(Em − Erev), where INa is the peak current, Em is the corresponding voltage, and Erev is the determined reversal potential. The data were fitted with the Boltzmann equation gm/gmax = 1/{1 + exp((E0.5 − E)/kE)}, where gmax is the maximum conductance, E0.5 is the voltage at which g/gmax = 0.5, and kE is the slope factor. To obtain the inactivation curves, peak currents evoked by a test pulse were measured, normalized, and plotted against the conditioning prepulse potential. The data were fitted with the Boltzmann equation y = 1/{1 + exp((Epp − h0.5)/kh)}, where h0.5 is the voltage at which y = 0.5 and kh is the slope factor. To obtain half-maximal inhibitory concentration (IC 50 ) values, peak current amplitudes at different drug concentrations were normalized to the value obtained in control solution. The data were fitted with the Hill equation y = ymax × {IC 50 n/(IC 50 n × Cn)}, where ymax is the maximal amplitude, IC 50 the concentration at which y/ymax = 0.5, and n is the Hill coefficient.
RESULTS
We first questioned whether Intralipid and Lipofundin interact with Nav1.5 in a way that results in altered functional properties and with a decreased susceptibility of the channel to be inhibited by bupivacaine. When lipid resuscitation was performed in clinical practice, lipid plasma concentrations up to 1% were suggested to occur. 12 We, therefore, explored the effect of 1% Intralipid and 1% Lipofundin on different biophysical properties of Nav1.5. The voltage-dependent activation was examined before and after application (>3 minutes) of Intralipid or Lipofundin by 20-millisecond depolarizing test pulses from −90 to +50 mV in steps of 5 mV in cells held at −120 mV (Fig. 1A) . The voltage dependency for activation was not changed by Intralipid, that is, the half-maximal conductance in control solution (V 1/2 = −42 ± 0.2 mV) was not different in the presence of Intralipid (V 1/2 = −43 ± 0.2 mV, n = 6, P > 0.3, paired t test, Fig. 1B) . Accordingly, the reversal potential was not significantly changed (control: 42 ± 1 mV vs Intralipid: 43 ± 1 mV, n = 6, P > 0.1, paired t test). Identical experiments with 1% Lipofundin revealed similar data, that is, the voltage dependency of activation (control V 1/2 = −45 ± 0.6 mV vs Lipofundin −44 ± 0.6 mV, n = 8, P > 0.2, paired t test) and the reversal potential (control: 44 ± 1 mV vs Lipofundin: 45 ± 1 mV, n = 6, P > 0.4, paired t test) were not changed.
We then studied the effects of both lipid emulsions on voltage-dependent fast inactivation and on the time course for the recovery from fast inactivation at −120 mV. As is demonstrated in Figure 1C , 1% Intralipid induced a 7-mV strong hyperpolarizing shift (7 ± 2 mV, n = 11) of the steadystate fast inactivation from V 1/2 of −57 ± 0.2 mV in control solution to V 1/2 of −64 ± 0.3 mV (n = 11). The time course for recovery from inactivation was well fitted with a single exponential potential, revealing a significantly slower recovery in the presence of 1% Intralipid (τ = 10.4 ± 0.3 milliseconds, n = 8) as compared with control solution (τ = 5.5 ± 0.2 milliseconds, n = 8, P < 0.05, paired t test) ( Fig. 1D) . One percent Lipofundin also induced a hyperpolarizing shift (10 ± 1 mV, n = 9) of steady-state fast inactivation.
Neither of the observed effects of the 2 lipid emulsions revealed a plausible mechanism for lipid resuscitation. Instead, they rather suggest that both emulsions reduce the availability of Nav1.5. To further substantiate these data, we explored whether Intralipid or Lipofundin reduce peak current amplitudes of Nav1.5 and thus act as channel inhibitors. Currents were activated by 10-millisecond test pulses to −10 mV at 0.1 Hz in cells held at −120 mV. Intralipid did not induce a significant inhibition of current amplitudes at concentrations up to 3% (−3% ± 3% block, n = 9, P > 0.3, paired t test, Fig. 2 , A and C). To investigate whether inhibition was significant on inactivated channels, currents were activated by test pulses to −10 mV after inactivating 10-second prepulses to −70 mV (prepulse −70 mV) and an interval of 100 milliseconds to allow recovery from fast inactivation. However, inactivated channels were not significantly more sensitive for block by Intralipid as compared with resting channels (3% Intralipid: 13% ± 5% block, n = 9, P > 0.08, unpaired t test, Fig. 2C ). Identical experiments with 3% Lipofundin revealed a quite prominent and highly significant reduction of the peak current amplitudes (42% ± 4% block, n = 10, P < 0.001, paired t test, Fig. 2B ). However, this effect was not influenced by the amount of inactivated channels (42% ± 5% block, n = 6, P > 0.9, unpaired t test, Fig. 2D ). Neither of the 2 lipid emulsions at 1% induced a significant use-dependent block examined at 10 Hz (data not shown).
We then asked whether any of the 2 lipid emulsions significantly alter the ability of bupivacaine to inhibit Nav1.5. Without lipid emulsions in the external recording solution, tonic block by bupivacaine revealed the IC 50 values of 50 ± 4 µM (n = 16) for resting channels (V h = −120 mV) and 2 ± 0.2 µM (n = 10) for inactivated channels (prepulse −70 mV, Fig. 3, A and B ). The addition of 1% or 5% Intralipid to the external solution resulted in a prominent rightward shift of Figure 1 . Effects of 1% Intralipid® on functional properties of Nav1.5 in human embryonic kidney 293 cells. A, Representative current traces of Nav1.5 activated by 20-millisecond test pulses from −90 to +50 mV with 5 mV increments in control solution. B, Normalized conductance (C/C max ) of Nav1.5 in the absence and presence of 1% Intralipid. The conductance was calculated by the equation gm = INa/(Em − Erev), where INa is the peak current, Em is the amplitude of the voltage step, and Erev is the estimated reversal potential. Values were normalized to the maximal value, plotted against the voltage, and fitted by the Boltzmann function. C, Shift of steady-state inactivation of Nav1.5 by 1% Intralipid®. Twenty-millisecond prepulses from −120 to +20 mV in steps of 5 mV were followed by a 20-millisecond test pulse to −10 mV. The holding potential was −120 mV. Current amplitudes were normalized to the value obtained at the first pulse, plotted against the corresponding voltage, and fitted with the Boltzmann function. D, Average time course of the recovery from fast inactivation of Nav1.5 without and with 1% Intralipid®. One hundred-millisecond prepulses to −10 mV were followed by increasing time intervals at −120 mV and by a 20-millisecond-long test pulse to −10 mV. Current amplitudes were normalized with respect to the maximal values obtained at the end of the protocol, plotted against the interval time, and fitted with a single exponential function. Data are presented as mean ± SEM. Statistical comparisons of fitted data depicted in B, C, and D were calculated with the paired t test. Bupivacaine also induces a strong use-dependent block, an effect that might be relevant in terms of cardiac toxicity. Accordingly, 10 µM bupivacaine induced a pronounced usedependent block when a train of 60 test pulses was applied at 10 Hz (37% ± 2% block, n = 8, Fig. 4A ). When 1% Intralipid (23% ± 2% block, n = 8, Fig. 4 , B and C) or 1% Lipofundin (18% ± 1% block, n = 8, Fig. 4D ) was added to 10 µM bupivacaine, use-dependent block was significantly reduced (P < 0.01 for both emulsions, unpaired t tests). The reduction of use-dependent block was significantly more pronounced for Lipofundin than for Intralipid (P < 0.001, unpaired t test).
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Another potentially cardiotoxic property of bupivacaine is a slow dissociation from inactivated channels. 13, 18 We, therefore, investigated the time course for recovery from block by 10 µM bupivacaine in the absence or presence of lipid emulsions. Cells were held at −120 mV and test pulses to −10 mV were applied, after interpulses with variable lengths at −120 mV and a 10-second-long prepulse to −70 mV. As is demonstrated in Figure 5 , the current recovered with a time course covering 2 time constants (τ1 and τ2). In the control solution, a large fraction (approximately 90%) of the current recovered with the fast time constant (τ1 = 8 ± 1 milliseconds) and a smaller fraction (approximately 10%) with the slower time constant (τ2 = 122 ± 51 milliseconds, n = 8). In presence of 10 µM bupivacaine, approximately 48% of the current recovered fast (τ1 = 29± 3 milliseconds), and approximately 52% recovered with the slow time constant (τ2 = 2377 ± 298 milliseconds, n = 8). It was suggested that τ2 reflects the recovery of inactivated channels from which bupivacaine dissociates very slowly. 18 Application of 1% Intralipid to 10 µM bupivacaine largely reversed the effects of bupivacaine applied alone (Fig. 5A ). The dissociation time constants decreased (τ1 = 15 ± 1 milliseconds and τ2 = 775 ± 261 milliseconds, n = 8) (P < 0.05, respectively, <0.01, unpaired t test), and the estimated fraction of channels with a slow time constant was reduced (fast approximately 84%, slow approximately 16%). A similar effect was also observed with 1% Lipofundin (τ1 = 18 ± 1 milliseconds and τ2 = 1303 ± 223 milliseconds, Fig. 5B ) (P < 0.05 for both time constants, unpaired t test). Although none of the 2 time constants revealed a significant difference between Intralipid and Lipofundin (P > 0.7 for τ1 and 0.1 for τ2, unpaired t tests), the estimated fraction of channels with a slow time constant (approximately 52%) was not markedly reduced in the presence of Lipofundin as compared with control solution. . Currents were activated by 10-millisecond test pulses from −120 to −10 mV in intervals of 10 seconds. C and D, Concentration-dependent tonic block of Nav1.5 by Intralipid (C) or Lipofundin (D) examined at the holding potential (V h ) of −120 mV for resting channels or after 10-second prepulses to −70 mV and a 100-millisecond interval at −120 mV for inactivated channels. Peak current amplitudes at different drug concentrations were normalized with respect to the peak amplitude in control solution and plotted against the concentration of the respective lipid emulsion. The dotted lines were drawn to guide the eye. Data are presented as mean ± SEM, and statistical analysis of the degree of inhibition by 3% lipid emulsion was calculated with the paired t test.
DISCUSSION
In this study, we investigated the effects of lipid emulsions and bupivacaine on the cardiac sodium channel Nav1.5, a key molecule for cardiac toxicity of bupivacaine. Both Intralipid and Lipofundin seem to functionally interact with Nav1.5, however, in a manner that is more likely to decrease than to increase channel availability. Lipofundin even induced a voltage-independent tonic block of Nav1.5. On the contrary, both lipid emulsions were able to significantly reverse bupivacaine-induced block on Nav1.5.
It is important to note that this study has several limitations. The experimental conditions under which our patch-clamp experiments were performed cannot be compared with the situation in vivo. The stock solution of bupivacaine (dissolved in DMSO) and the lipid emulsions were both diluted in waterbased test solutions, allowing regular patch-clamp recordings. The solubility and distribution of both bupivacaine and lipids in human plasma are of course more complex and cannot be perfectly mimicked in this cellular approach. Nav1.5 is only 1 of many molecules in cardiomyocytes that are targeted by bupivacaine. Our study was designed to specifically investigate the effects of bupivacaine and lipid emulsions on Nav1.5, thus we used human embryonic kidney 293 cells as a simplified expression system to investigate human Nav1.5. Further studies of other membrane molecules as well as of native cardiac myocytes would be helpful to further unravel the molecular mechanisms by which lipid emulsions can alleviate cardiotoxicity induced by local LAs. Figure 3 . State-dependent tonic block of Nav1.5 by bupivacaine without and with Intralipid® or Lipofundin®. A, Representative current trace of Nav1.5 in the presence of increasing bupivacaine concentrations. Currents were activated by 10-millisecond test pulses from −120 to −10 mV in intervals of 10 seconds. The holding potential was −120 mV. B, Concentration-dependent tonic block of resting and inactivated Nav1.5 by bupivacaine. Resting channels were examined at V h = −120 mV and inactivated channels after 10-second prepulses to −70 mV followed by a 100-millisecond interval at −120 mV. Peak current amplitudes at different drug concentrations were normalized with respect to the peak amplitude in the control solution, plotted against the concentration of bupivacaine, and fitted with the Hill equation. C to F, Concentrationdependent inhibition of resting (C, E) or inactivated (D, F) Nav1.5 by bupivacaine in control solution or in the presence of 1% and 5% Intralipid (C, D) or Lipofundin (E, F). Data are presented as mean ± SEM, and statistical comparisons of fitted data depicted in C to F were calculated with the unpaired t test. Due to multiple comparisons of fitted data in each of these figures, the significance level was corrected to P < 0.017 with the Bonferroni post hoc test.
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Both emulsions counterintuitively decreased the availability of Nav1.5, and Lipofundin even induced a tonic block of current amplitudes. A number of reports from Xiao et al. [19] [20] [21] demonstrate that fatty acids directly bind to Nav1.5 and exhibit a rather potent and state-dependent channel inhibition, by interacting with the suggested intracellular binding sites for local LAs. Soybean oil contains these Nav1.5-blocking polyunsaturated fatty acids, including linolenic acid, linoleic acid, and oleic acid. 21 In contrast, Intralipid (200 g/L) contains more soybean oil than Lipofundin (100 g/L). Moreover, the inhibitory effect by Lipofundin was not state dependent. Therefore, we cannot postulate a significant role of fatty acids for the inhibitory effects of lipid emulsions on Nav1.5 observed in our study.
In our study, both lipid emulsions partly reduced the blocking potency of bupivacaine on Nav1.5. Both emulsions shifted the dissociation constant of bupivacaine-induced block to higher concentrations and partly reduced usedependent block by bupivacaine at 10 Hz. While Intralipid seemed to be more efficient than Lipofundin to abrogate tonic block, the use-dependent block was more efficiently reduced by Lipofundin. This observation is of potential relevance, as the prominent use-dependent block by bupivacaine is a possible key mechanism for the high cardiac toxicity. Another potentially cardiotoxic feature of bupivacaine is a slow dissociation from inactivated channels. 13, 18 Both emulsions slowed down recovery from fast inactivation when applied without bupivacaine. In contrast, we observed a rather impressive effect on the recovery from slow inactivation by both Intralipid and Lipofundin when coapplied with bupivacaine. Both emulsions partly antagonized the effects of bupivacaine on the recovery from inactivation, and this effect seemed to be more prominent for Intralipid as compared with Lipofundin. This experiment Figure 5 . Recovery of inactivated Nav1.5 channels from block by bupivacaine without or with 1% Intralipid® (A) or 1% Lipofundin® (B). Tensecond prepulses to −70 mV were followed by a variable (0-3043.3 milliseconds) interpulse at −120 mV and a 10-millisecond test pulse to −10 mV. Peak current amplitudes were normalized to the maximal value obtained at the end of the protocol, plotted against the length of the interpulse, and best fitted with a double-exponential function to reveal 2 time constants. Data are presented as mean ± SEM, and statistical comparisons of fitted data were calculated with the unpaired t test. . Use-dependent block of Nav1.5 by 10 µM bupivacaine at 10 Hz with and without 1% Intralipid® or Lipofundin®. A and B, Representative current traces of Nav1.5 for use-dependent block by 10 µM bupivacaine without (A) and with 1% Intralipid (B). Currents were activated at 10 Hz with trains of sixty 10-millisecond pulses to −10 mV (V h = −120 mV). C and D, Use-dependent block of Nav1.5 by 10 µM bupivacaine with 1% Intralipid (C) or 1% Lipofundin (D). Peak currents were normalized to the amplitude of the first pulse and plotted against the pulse number. Data are presented as mean ± SEM, statistical analysis of the degree of inhibition at the last pulse was calculated with the unpaired t test.
indicates that both emulsions induced a faster dissociation of bupivacaine from inactivated channels, and we argue that this effect might be of relevance.
Taking into consideration that the maximum tolerated systemic concentration of bupivacaine in humans averages 4 µg/mL (14 µM), 22 our experimental setting with 10 µM bupivacaine and 1% lipid emulsion probably reflects the clinical in vivo situation fairly well.
Weinberg et al. 23 demonstrated that application of Intralipid increased the median lethal dose of bupivacaine in vivo. A likely explanation for this effect is the concept of a lipid sink, where the effective concentration of "free" bupivacaine is reduced by absorption into lipid vesicles. 10, 11 Some studies suggest that Intralipid is more efficient than Lipofundin to exhibit a lipid sink, 17 and, consequently, Intralipid was shown to be more effective than Lipofundin for treatment of bupivacaine-induced arrhythmias. 16 It should also be mentioned that other studies did not find a relevant difference between Intralipid and Lipofundin, 6 or even implicate that Lipofundin® is more efficient than Intralipid® in absorbing bupivacaine from human plasma. 24 We have the overall impression that Intralipid is superior to Lipofundin in abrogating bupivacaine-induced block of Nav1.5, with the exception of use-dependent block. As discussed by Zausig et al., 25 it is possible that application of quite large volumes of lipid emulsions simply lead to a dilution of bupivacaine in plasma. In our defined test solutions, we can exclude that dilution contributes to the observed effects.
An alternative explanation for the observed effects of lipid emulsions in our study is that free fatty acids could occupy the LA binding site and competitively prevent or abrogate bupivacaine-induced inhibition. A recent crystal structural model of the voltage-gated sodium channel NavAb suggests that lipids might be able to access the local LAs binding site via membrane-facing side fenestrations of the channel pore. 26 It is possible that lipids enter the pore via these fenestrations to mask the LA binding site and to modulate channel gating. As a consequence, bupivacaine would be prevented from interacting with the LA binding sites and its inhibitory potency reduced. Another recent study suggests that fatty acids can indeed antagonize bupivacaineinduced tonic and use-dependent block of Nav1.5. 27 Fatty acids (linolenic and stearic acid) impressively reduced bupivacaine-induced block of Nav1.5. The authors suggested that their data could be explained by fatty acids interacting with the LA binding site. Moreover, they noted that bupivacaine-induced block was more efficiently antagonized by linolenic acid (polyunsaturated) than by stearic acid (saturated). As Intralipid contains more polyunsaturated fatty acids than Lipofundin, this difference could contribute to the apparent advantages of Intralipid over Lipofundin. Future studies in more intact preparations would be helpful to address this possibility.
Bearing in mind the limitations of our study, our data suggest that lipid emulsions are likely to functionally interact with cardiac sodium channels and to reduce inhibition by bupivacaine. These effects might be achieved by absorption and thus reflect the concept of a lipid sink. However, our data also sustain the possibility of more specific mechanisms that need to be examined in further studies. E
